Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn the safety of adding 3 different
dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation
in patients with prostate cancer.